Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term neu. Found 9 abstracts

Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy. 2012 May;61(5):629-41.
Hayashi N, Nakamura S, Tokuda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Serum HER2 levels determined by two methods in patients with metastatic breast cancer. International Journal of Clinical Oncology. 2012 Feb;17(1):55-62.   PMCID: *
Freedman GM, Anderson PR, Li TY, Nicolaou N. Locoregional Recurrence of Triple-negative Breast Cancer After Breast-conserving Surgery and Radiation. Cancer. 2009 Jan;115(5):946-51.
Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. International Journal of Oncology. 2007 Feb;30(2):509-20.
Cohen SJ, Meropol NJ. Drug development in pancreatic cancer - Finally, biology begets therapy. International Journal of Gastrointestinal Cancer. 2002 Jan;32(2-3):91-106.
Adams GP, McCartney JE, Wolf EJ, Eisenberg J, Huston JS, Bookman MA, Moldofsky P, Stafford WF, Houston LL, Weiner LM. Enhanced Tumor Specificity of 741f8-1(Sfv')(2), an Anti-C-Erbb- 2 Single-Chain Fv Dimer, Mediated by Stable Radioiodine Conjugation. Journal of Nuclear Medicine. 1995 Dec;36(12):2276-81.
Testa JR, Getts LA, Salazar H, Liu ZM, Handel LM, Godwin AK, Hamilton TC. Spontaneous Transformation of Rat Ovarian Surface Epithelial- Cells Results in Well to Poorly Differentiated Tumors with a Parallel Range of Cytogenetic Complexity. Cancer Research. 1994 May 15;54(10):2778-84.
Sauter ER, Keller SM, Erner S, Goldberg M. Her-2/Neu - a Differentiation Marker in Adenocarcinoma of the Esophagus. Cancer letters. 1993 Nov 30;75(1):41-4.
Sauter ER, Keller SM, Erner S, Goldberg M. HER-2/neu: A differentiation marker in adenocarcinoma of the esophagus. Cancer letters. 1993 Jan;75(1):41-4.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term neu

neu her-2 carcinoma protein survival expression HER-2 breast cancer amplification HER2 overexpression tyrosine kinase inhibitor first-line therapy tumor localization Differentiation marker vaccines ENDOMETRIAL advanced colorectal-cancer basal-like breast cancer c-erbb-2 protein overexpression Her-2 carcinomas c-erbb-2 oncogene human-breast monoclonal-antibodies phase-i trial Serum HER2 oncogene amplification SURGICAL ADJUVANT BREAST clinical utility FTI proto- binding esophageal adenocarcinoma egf receptor cell differentiation p-iodobenzoate receptor ESTROGEN-RECEPTOR myc protooncogene esophagus cancer Breast neoplasm chromosome-aberrations colony-stimulating factor Dendritic cell Ovarian cancer-Vaccine-Clinical trial-Consolidation therapy growth-factor receptor breast-cancer regulatory t-cells EGFR pancreatic cancer Esophageal adenocarcinoma extracellular domain gene expression sites neu oncogene cancer farnesyl-protein transferase gene oncoprotein erbb-2 AROMATASE INHIBITOR immunotherapy fulvestrant oncogenes peptide trastuzumab-based therapy VEGF GENE-TRANSCRIPTION tumor-cells radiotherapy GROWTH-FACTOR RECEPTOR Trastuzumab tumor-associated antigen immune-response TAMOXIFEN RESISTANCE heterozygosity matrix metalloproteinase inhibitors hormone receptor-negative tumor marker c- oncogene tumor matrix-metalloproteinase inhibitor DOUBLE-BLIND single-chain fv molecules CANCER differentiation marker radioiodination targeted therapy Biological Tumor Markers lymphocytes RANDOMIZED-TRIAL POSTMENOPAUSAL WOMEN Metastasis progression-free survival monoclonal-antibody
Last updated on Thursday, April 02, 2020